KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Invested Capital (2020 - 2025)

Historic Invested Capital for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $1.1 billion.

  • Recursion Pharmaceuticals' Invested Capital rose 9818.14% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 9818.14%. This contributed to the annual value of $1.0 billion for FY2024, which is 12508.28% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Invested Capital stood at $1.1 billion, which was up 9818.14% from $927.9 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Invested Capital ranged from a high of $1.1 billion in Q3 2025 and a low of -$233.0 million during Q1 2021
  • In the last 5 years, Recursion Pharmaceuticals' Invested Capital had a median value of $493.6 million in 2022 and averaged $560.7 million.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Invested Capital surged by 36319.29% in 2021, and later plummeted by 3522.32% in 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' Invested Capital (Quarter) stood at $542.9 million in 2021, then dropped by 10.52% to $485.8 million in 2022, then fell by 4.6% to $463.5 million in 2023, then soared by 125.08% to $1.0 billion in 2024, then increased by 1.21% to $1.1 billion in 2025.
  • Its Invested Capital was $1.1 billion in Q3 2025, compared to $927.9 million in Q2 2025 and $942.5 million in Q1 2025.